Acquiring Company
MDxHealth
Acquired Company
Exosome Diagnostics
WalthamBiotechnologyHealth CareBiotechnologyHealthcareHealth CareHealth DiagnosticsDescription
MDxHealth has finalized the acquisition of Exosome Diagnostics from Bio-Techne for $15 million. The deal, announced on September 15, 2025, includes the ExoDx Prostate test and related assets. This acquisition is part of MDxHealth’s strategy to enhance its precision diagnostics portfolio. The payment will be structured over multiple years.
Quick answer
MDxHealth is acquiring Exosome Diagnostics for $15 million, announced September 15, 2025.
- How much did MDxHealth pay for Exosome Diagnostics?
- The reported deal value is $15 million.
- What does MDxHealth do?
- Mdxhealth SA is a company focused on urology and prostate cancer diagnostics.
- Where are MDxHealth and Exosome Diagnostics based?
- Exosome Diagnostics is based in Waltham, Massachusetts, United States.
- Who are the decision-makers at MDxHealth?
- Fundz holds 1 contact at MDxHealth. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Health Diagnostics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie acquires Bretisilocin for mental health expansion (October 15, 2025)
- Avanos Medical acquires Nexus Medical for growth (September 15, 2025)
- Edwards Lifesciences acquires Vectorious for $497M, $497M (September 4, 2025)
- AbbVie completes acquisition of Capstan Therapeutics (August 19, 2025)
- Terumo Corporation acquires OrganOx Ltd. (October 30, 2025)
- Novartis to acquire Tourmaline Bio in tender offer (October 22, 2025)
Who to call at MDxHealth, and when
When MDxHealth changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day MDxHealth raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at MDxHealth, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at MDxHealth. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment MDxHealth makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Exosome Diagnostics?
Exosome Diagnostics was acquired by MDxHealth. The deal was reported on September 15, 2025. Mdxhealth SA is a company focused on urology and prostate cancer diagnostics. It develops and provides tools that help health care professionals in decision-making processes regarding prostate health. MDxHealth is publicly traded (MDXH) and operates in Biotechnology.
When did MDxHealth acquire Exosome Diagnostics?
MDxHealth's acquisition of Exosome Diagnostics was reported on September 15, 2025. MDxHealth has finalized the acquisition of Exosome Diagnostics from Bio-Techne for $15 million. The deal, announced on September 15, 2025, includes the ExoDx Prostate test and related assets. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Exosome Diagnostics do?
Exosome Diagnostics, Inc. specializes in non-invasive testing to help guide patient treatment decisions in oncology and other areas. Their flagship product is the ExoDx Prostate test, which provides actionable information regarding prostate cancer. It is privately held, operating in Biotechnology, and is based in Waltham.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.